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Abstract
More than 200 generic drugs approved by the U.S. Food and Drug Administration
for non-cancer indications have shown promise for treating cancer. Due to their
long history of safe patient use, low cost, and widespread availability, repurposing
of generic drugs represents a major opportunity to rapidly improve outcomes for
cancer patients and reduce healthcare costs worldwide. Evidence on the efficacy of
non-cancer generic drugs being tested for cancer exists in scientific publications,
but trying to manually identify and extract such evidence is intractable. In this paper,
we introduce a system to automate this evidence extraction from PubMed abstracts.
Our primary contribution is to define the natural language processing pipeline
required to obtain such evidence, comprising the following modules: querying,
filtering, cancer type entity extraction, therapeutic association classification, and
study type classification. Using the subject matter expertise on our team, we
create our own datasets for these specialized domain-specific tasks. We obtain
promising performance in each of the modules by utilizing modern language
modeling techniques and plan to treat them as baseline approaches for future
improvement of individual components.
1 Introduction
Each year around the world, nearly 10 million people die from cancer [2] and the cost of cancer
exceeds USD $1 trillion [1]. Finding new therapeutic uses for inexpensive generic drugs ("drug
repurposing") can rapidly create affordable new treatments. Hundreds of non-cancer generic drugs
have shown promise for treating cancer, but it is unclear which are the most worthwhile repurposing
opportunities to pursue. Scientific publications such as preclinical laboratory studies and small clinical
trials contain evidence on generic drugs being tested for cancer use. The Repurposing Drugs in
Oncology (ReDO) project, through manually inspecting research articles indexed by PubMed, found
anti-cancer evidence for more than 200 non-cancer generic drugs [15, 4, 19]. However, manual review
to identify and analyze potential evidence is time-consuming and intractable to scale. As PubMed
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Figure 1: Solution overview: Input to the evidence discovery pipeline is a list of non-cancer generic
drugs, and the output is published scientific evidence for each drug for treating various cancer types.
indexes millions of articles and the collection is continuously updated, it is imperative to devise
(semi)automated techniques to synthesize the existing evidence. Machine learning (ML)-powered
evidence synthesis would provide a comprehensive and real-time view of drug repurposing data and
enable actionable insights. To this end, we must achieve task automation, algorithmic accuracy, and
technical scalability in three key areas: evidence identification, extraction, and synthesis.
The work presented in this paper is part of an ambitious initiative to synthesize the plethora of
scientific and real-world data on non-cancer generic drugs to identify the most promising therapies to
repurpose for cancer. This type of endeavor requires close collaboration between experts in different
disciplines, such as cancer research (to provide guidance, annotate datasets, and verify results),
machine learning (to devise machine learning tasks, select datasets to be annotated, devise models,
and evaluate performance), and software engineering (to incorporate models in end-to-end online
applications). Furthermore, implementing repurposed therapies as the standard of care in medical
practice requires definitive clinical trials, new incentives and business models to fund them, and
engagement by various stakeholders such as patients, doctors, payers, and policymakers. In this paper,
we focus on the key aspect of identifying and extracting relevant evidence from PubMed articles.
Methods for synthesizing drug repurposing evidence can be divided into three major categories:
network-based methods, natural language processing (NLP) approaches, and semantic techniques [20].
Network-based approaches aim to infer relationships between biological entities (drug–disease or
drug–target relationships), inspired by the fact that biologic entities (disease, drug, protein, etc.) in
the same module of biological networks share similar characteristics [12]. NLP approaches aim to
both identify biological entities and mine new knowledge from scientific literature [10]. Semantic
approaches require a semantic network to be built first, which can be used with various approaches to
mine relationships between entities [14]. We focus on NLP approaches. Our primary contributions,
described in detail in the remainder of this paper, are as follows: formulating the pipeline of NLP
tasks required to identify relevant evidence of generic drug repurposing for cancer from PubMed
articles, precisely specifying the NLP tasks in terms of input and output (not an easy endeavor),
Creating domain-specific datasets that support the task definition, designing and evaluating initial
models for each of the domain-specific tasks.
2 NLP Pipeline and Dataset for Drug-Cancer Evidence Extraction
PubMed, provided by the National Center for Biotechnology Information (NCBI), is a comprehensive
source of biomedical studies, comprising more than 30 million biomedical abstracts and citations
from various sources such as MEDLINE, life science journals, and online books. Given a list of
generic drugs, the goal of our work is to automatically select abstracts from the large PubMed
collection, that measure cancer-relevant phenotypic outcomes of interventions with generic drugs.1
We propose an evidence discovery pipeline, shown in Figure 1. First we query PubMed using a
strategy inspired by the Cochrane highly sensitive search (CHSS) strategy [6] to narrow the collection
of articles we analyze. Note that querying PubMed, even with a sophisticated search string, may not
yield only relevant articles. Hence we have a (shallow) filtering stage to reject the easy irrelevant
1Phenotype is the observable physical properties of an organism; these include the organism’s appearance,
development, and behavior. We focus on phenotypic outcomes (such as proliferation/death of cells grown in
culture or tumor progression/overall survival rates for clinical trials) since they are a more direct measure of
outcomes that matter to cancer patients and represent stronger therapeutic evidence (as opposed to, for example,
the effects of drugs on protein levels).
2
Retinoids can block cell proliferation and induce apoptosis in tumor
cells. The antitumoral effect of synthetic retinoids like Adapalene (ADA)
on hepatoma cells (HepG2, Hep1B) was investigated. ADA at 10(-4)M
efficiently induced apoptosis, reaching 61.7% in HepG2 and 79.1% in
Hep1B after 72 h incubation. This was accompanied by up-regulation of
pro-apoptotic bax and caspase 3, while bcl-2 was down-regulated,
shifting the bax/bcl-2 ratio to >2.3 in hepatoma cells. ADA inhibits
hepatoma cell growth in vitro and is a powerful inducer of hepatoma
cell apoptosis.
1
Figure 2: Sample relevant abstract annotation. PubMed # 15105045, Adapalene is the non-cancer
generic drug, used to treat hepatoma cancer. It is a preclinical evidence (in vitro study), and has an
effective association. Evidence for association with phenotypic outcome measured is italicized.
Coarse-level Association Count
Irrelevant No relation to cancer 553
No phenotypic outcome 155
Relevant
Effective 555
Detrimental 50
Inconclusive 216
No effect 68
Study type Count
Preclinical 318
Clinical observational study 107
Clinical trial 69
Other 28
Table 1: Dataset statistics for therapeutic association distribution (left) and study type distribution
(right) for the relevant abstracts.
cases. Using the resulting abstracts, cancer types are identified using a named entity recognition
(NER) model. With the abstract and pairs of drug-cancer types, therapeutic association is classified
and also the type of study is categorized. We refer to this collection of information (i.e., drug, cancer,
therapeutic association, study type) as the evidence discussed in the PubMed abstract.
The therapeutic association schema contains the following classes: 1. Irrelevant: A. Drug has no
relation to cancer (cases where either the drug or the cancer is not the focus of the study); B. Abstract
does not discuss a phenotypic outcome and 2. Relevant: A. Effective: the drug was shown to be
effective for treating the cancer; B. Detrimental: the drug has a detrimental effect on the cancer; C. No
effect: the drug has no effect on the cancer; D. Inconclusive: the results of the study are inconclusive.
The study types we consider are defined as follows: preclinical studies (in vitro, in vivo), observational
studies (including case reports), and clinical trials.
Identifying such evidence from scientific abstracts is not trivial. The articles that discuss cancer
interventions use domain-specific jargon which makes the text hard to comprehend by both humans
with non-expert background and machines that are not trained with domain-specific data. Hence
a strong collaboration between domain-experts and data scientists is required to define machine
learning tasks, collect and annotate the appropriate information and design and evaluate machine
learning models that address the designed tasks. Due to space limitations, we cannot elaborate in
this paper on all difficulties in manually annotating datasets for all these tasks. We will refer to them
during the presentation of our work. An example of an annotated abstract is shown in Figure 2.
Our team of machine learning and biomedical scientists worked closely together to fine-tune the
querying and filtering strategy and to annotate cancer types, along with the therapeutic associations
and study types. In the interest of space, we present the results of the dataset creation in Table 1
without the details of the iterative process of producing it.
3 Models for Cancer Type, Therapeutic Association, and Study Type
We briefly discuss the models and their performance for cancer entity extraction, therapeutic associ-
ation classification, and study type classification, which form the key components of the proposed
evidence discovery pipeline.
3.1 Cancer Type Extraction
For cancer entity identification, we use two main named entity recognition (NER) methods. We train
sequential token-level IOB (inside, outside, beginning) tag prediction model using the BioNLP13CG
dataset [17]. Tokens that are not of interest are treated as ‘O’. We use the well-known conditional
3
Class Log. Reg DAN SciBERT
Irrelevant 0.83 0.81 0.81
Relevant 0.80 0.79 0.85
Table 2: Binary therapeutic association classification
Class Log. Reg DAN SciBERT
No relation 0.74 0.71 0.80
No phenotypic outcome 0.30 0 0.34
Effective 0.72 0.67 0.73
Detrimental 0.12 0 0.33
No effect 0.18 0 0.18
Inconclusive 0.30 0.03 0.25
Class PT BoW MeSH All
Preclinical 0.86 0.96 0.95 0.96
Clinical observational study 0.25 0.81 0.66 0.84
Clinical trial 0.78 0.78 0.60 0.80
Other 0.38 0.34 0.37 0.40
Table 3: Fine-grained therapeutic association classification (left) and Study type classification using
logistic regression (right).
random field (CRF) [18] and convolutional neural network (CNN) based SpaCy models [7] for entity
extraction. We evaluate the performance on the 1085 abstracts using recall2 with exact match and a
token-level overlap score [13], where the predicted entity with highest overlap is used to compute
the score. The CRF-based model obtains a recall of 54.2% and an overlap score of 66.4%, while the
SpaCy-based model presents higher performance of 67.7% recall and 77.6% overlap score.
3.2 Therapeutic Association Classification
Given a drug-cancer pair and the corresponding abstract text, we build three different models
for therapeutic association classification: 1. Logistic Regression with feature vectors that are a
concatenation of term frequency bag-of-words representations of abstracts, drug and cancer type
[9]; 2. Deep Averaging Networks (DAN): similar to logistic regression, except that the tokens of
abstract, drug and cancer type are initialized with word vectors trained using skip-gram objective over
a large set of PubMed abstracts [16]; the text of a given abstract is passed through deep averaging
networks [8] where the word vectors are re-trained (with the training data and classification objective),
and the representations of abstract, drug and cancer type are concatenated, and passed through a
final logistic layer; and 3. SciBERT [5, 3]: The drug and cancer type entities are encapsulated with
special characters and concatenated with the input abstract text. The task is framed as a multi-class
classification problem. The sequence representation is obtained using SciBERT’s encoding of the
[CLS] token3 (from the last hidden layer). This encoding captures the entire sequence representation
and is used for the multi-class classification with a logistic layer.
We perform a 5-fold cross-validation split at the document level, and evaluate performance for drug-
cancer type pairs, given the abstract text. Note that we use gold-standard cancer type annotations for
this analysis. We evaluate two different settings to understand the complexity of the task: (1) irrelevant
vs. relevant binary classification (Table 2) and (2) all six classes (Table 3, left side). Performance is
measured using F-score. SciBERT performs the best in most cases.
3.3 Study Type Classification
We train logistic regression models with different choices of features [11]: bag-of-words (BoW),
publication type (PT), MeSH terms and combining all. Results using logistic regression with different
choices of features are given in Table 3 (right side). Performance is measured using F-score. Using
all the features together provides the best performance.
4 Conclusion and Future Work
We proposed an end-to-end evidence discovery pipeline that fetches potential candidate abstracts
from PubMed for further evaluation with the goal of identifying non-cancer generic drug activity
against different cancer types. We discuss the components in the pipeline, and use NLP approaches
along with a number of well-thought-out heuristics to provide solutions for each component.
2Ratio between count of unique cancer entities predicted correctly by the model and number of unique cancer
entities.
3[CLS] is inserted as a special beginning token for every input sequence.
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